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Objective: Cancer staging is dynamic, reflecting accrual of knowledge and experi-
ence in treatment. The objectives of this study were to assess current esophageal
cancer staging and to determine whether refinements of classification and stage
grouping are necessary.
Methods: From 1983 through November 2000, 480 patients underwent esophagec-
tomy without induction therapy. Depth of tumor invasion (T), regional lymph node
status (N), distant status (M), number of metastatic regional lymph nodes, and
histopathologic type and grade were subjected to survival-tree analysis, multivari-
able Cox and hazard function analysis, and residual misclassification risk analysis.
Results: Inhomogenity of survival was found within and lack of distinction was
found between current American Joint Committee on Cancer staging groups,
supporting the need for refinement. T1 and N1 were redefined on the basis of
survival differences. T1a is intramucosal cancer, T1b is submucosal cancer (P 
.008), N1 is 1 or 2 metastatic regional lymph nodes, and N2 is 3 or more metastatic
regional lymph nodes (P  .01). Current subclassification of M1 is not warranted
(P  .9). Histopathologic type (P  .17) and grade (P  .3) minimally refined
staging. Reassignment of staging groups constrained by American Joint Committee
on Cancer definitions of stages 0 and IV produced less monotonic, distinctive, and
homogeneous survival than free assignment of staging groups.
Conclusions: Current American Joint Committee on Cancer staging of esophageal
cancer is inadequate. Refinement requires redefinition of T1, N1, and M1 classifi-
cations. Stage grouping within the constraints of American Joint Committee on
Cancer definitions produces less accurate prognosis than free assignment based on
survival data.
Anatomic extent of a cancer is represented by the TNM classifica-tion, which is based on the dual premises that a cancer growslocally (T), spreads to regional lymph nodes (N), and eventuallymetastasizes to distant sites (M) and that this progression isassociated with diminishing survival.1 In addition to anatomicextent, nonanatomic factors (eg, histopathologic type, histopatho-
logic grade, biologic markers, and age) might be important prognostic determinants.
For purposes of tabulation and analysis,1 TNM and nonanatomic classifications
are condensed into 5 major stage groupings with monotonic diminishing survival.
Between groupings, survival should be distinctive, and within each grouping,
survival should be homogeneous. The limits of staging groups have been set: stage
0 is high-grade dysplasia (HGD; in situ cancer), and stage IV is distant metastatic
disease.1 Only 3 groups (stages I, II, and III) remain for stage grouping between
these constraints.
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The AJCC Cancer Staging Handbook notes that “it is
essential to recognize the kinetics of change of staging
systems.”1 TNM classifications, additional factors, and
stage groupings should be dynamic, reflecting increasing
knowledge of cancer, its treatment, and its prognosis. Al-
though TNM staging of esophageal cancer was updated in
2002, experience with these classifications and stage group-
ings indicates that review and refinement are needed.
Therefore the purposes of this study were to determine
whether the present American Joint Committee on Cancer
(AJCC) staging of esophageal cancer adequately reflects
modern prognosis and, if not, to refine staging of esophageal
cancer by TNM reclassification, addition of other prognos-
tic factors, or stage regrouping.
Patients and Methods
Patients
From January 1983 to December 2000, 480 patients with esophageal
cancer who underwent resection without induction therapy were iden-
tified in the prospective esophageal surgery registry at The Cleveland
Clinic Foundation. The Clinic’s Institutional Review Board has ap-
proved research based on data contained in this registry.
Cross-sectional follow-up has been performed yearly. Fol-
low-up was incomplete in 2 patients last contacted in 1998, 5 and
12 years after surgical intervention. Median follow-up of all pa-
tients was 1.5 years, with 25% followed for more than 3.5 years.
Among 172 patients alive at last follow-up, median follow-up
was 3.4 years, with 25% followed for more than 6.9 years.
All-cause mortality (including operative) from the time of
esophagectomy was used to calculate survival estimates.
Staging
Current staging of esophageal cancer, modified for clarity, is
outlined in Table 1.
TABLE 1. Modified current TNM staging of esophageal
cancer
TNM classifications
T
Tis High-grade dysplasia*
T1 Tumor invading lamina propria,
muscularis mucosae, or submucosa†
T2 Tumor invading muscularis propria
T3 Tumor invading periesophageal tissue
T4 Tumor invading adjacent structures
N
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M‡
M0 No distant metastases
M1a Upper thoracic tumors metastatic to
cervical nodes
Lower thoracic tumors metastatic to
celiac nodes
M1b Other nonregional lymph node
metastases or distant metastases
Stage groupings
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage IIA T2 N0 M0
T3 N0 M0
Stage IIB T1 N1 M0
T2 N1 M0
Stage III T3 N1 M0
T4 N0-1 M0
Stage IVA T1-4 N0-1 M1a
Stage IVB T1-4 N0-1 M1b
*Termed carcinoma in situ in current AJCC and UICC classifications.
†Muscularis mucosae not included in current AJCC or UICC classifica-
tions.
‡Complexity of distant metastases has been simplified.
TABLE 2. Prevalence of pathologic tumor classification
(TNM), additional tumor features, and stage groupings
Characteristic No. % of 480
TNM classification
pT
Tis 44 9.2
1a 68 14
1b 41 8.5
2 49 10
3 267 56
4 11 2.3
pN
0 235 49
1 245 51
Metastatic nodes
0 235 49
1 45 9.4
2 43 9.0
3 26 5.4
4 131 27
pM
0 438 91
1a 26 5.4
1b 16 3.3
Tumor features
Histopathologic type
Adenocarcinoma 401 84
Squamous cell 67 14
Adenosquamous cell 9 1.9
Unclassified 3 0.6
Histopathologic grade
Well 97 20
Moderately well 10 2.1
Moderate 148 31
Moderately poor 35 7.3
Poor 186 39
Unclassified 4 0.8
AJCC stage groupings
0 44 9.2
I 98 20
IIA 88 18
IIB 28 5.8
III 180 38
IVA 26 5.4
IVB 16 3.3
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TNM classification. All staging was determined from exami-
nation of resected tissue at esophagectomy (pathologic stage). pT
was determined microscopically and categorized according to
maximum depth of invasion into each distinct esophageal layer.
Subclassification of pT was based on esophageal layer: epithelium
(HGD), lamina propria, muscularis mucosa, submucosa, muscu-
laris propria, periesophageal tissue, and adjacent structures. pN
was determined by microscopic examination of all resected re-
gional lymph nodes. Subclassification of pN was based on number
of regional lymph nodes containing metastatic cancer, although in
the analysis both this and the percentage of resected nodes con-
taining metastases were examined. The median number of nodes
examined in resection specimens was 11 (interquartile range,
5-18). pM was determined by preoperative clinical staging and
intraoperative assessment of distant sites within the surgical fields.
Subclassification of pM was based on metastases to specific non-
regional lymph nodes (pM1a, lower thoracic esophagus to celiac
lymph nodes or upper thoracic to supraclavicular lymph nodes)
and other nonregional lymph nodes or distant sites (pM1b). Pa-
tients’ TNM classifications are listed in Table 2.
Additional factors. Histopathologic type was assessed and
classified as adenocarcinoma, squamous cell cancer, and adeno-
squamous cell cancer (Table 2). Histopathologic grade was as-
sessed and classified as well differentiated (plus HGD), well to
moderately well differentiated, moderately differentiated, moder-
ately poor to poorly differentiated, and poorly differentiated (un-
differentiated) (Table 2).
Stage groupings. Current stage groupings are outlined in Ta-
ble 1. JCC guidelines constrain assignment of staging groups
between stage 0, HGD (in situ cancer), and stage IV, distant
metastatic disease (Table 2).
Methods
Adequacy of current staging. Monotonicity is strictly ordered
decreasing survival with increasing classification or grouping.
Distinctiveness is separation between monotonic classifications or
groupings based on survival. Homogeneity is absence of distinct
subclassifications or subgroups within classifications or groupings
based on survival.
Monotonicity, distinctiveness, and homogeneity of survival in
the context of current TNM classifications and stage groupings
were examined. Monotonicity was assessed by evaluating (1)
stratified survival curves for decreasing survival between classifi-
cations and groups and (2) coefficients of Cox proportional hazard
and nonproportional hazard function multivariable analyses. Dis-
Figure 1. Survival after esophagectomy according to T classification in pN0 M0 disease. A, Current classification.
Number of patients in each classification and number traced at 5 years, respectively, were as follows: Tis (44 and
21), T1 (98 and 26), T2 (31 and 8), T3 (57 and 12), and T4 (4 and 0). B, Proposed subclassification of T1 into T1a
(intramucosal, n  66, 18 traced at 5 years) and T1b (submucosal, n 32, 8 traced at 5 years). Shown for reference
are Tis (HGD) and T2. Vertical bars represent 68% confidence limits.
TABLE 3. Depth of tumor invasion and survival in pN0 M0
cancers
Classification
Coefficient
 SE P value
Hazard
ratio
95%
CL
Current classification*
T1 0.75 0.46 .10 2.1 0.87-5.2
T2 1.50 0.48 .002 4.5 1.74-11.5
T3 2.1 0.44 .0001 8.5 3.6-20
T4 2.4 0.71 .0006 11.3 2.8-46
Subclassifications of pT*
T1a (intramucosal) 0.40 0.51 .4 1.49 0.55-4.0
T1b (submucosal) 1.25 0.50 .01 3.5 1.30-9.3
T2 1.50 0.48 .002 4.5 1.74-11.5
T3 2.1 0.44 .0001 8.5 3.6-20
T4 2.4 0.71 .0006 11.4 2.8-46
Residual risk†
T1b (submucosal) 1.00 0.38 .008 2.7 1.30-5.7
T2 1.25 0.35 .0004 3.5 1.76-7.0
T3 1.90 0.29 .0001 6.7 3.8-11.7
T4 2.2 0.63 .0005 8.9 2.6-31
CL, Confidence limits.
*Compared with Tis tumors.
†Compared with Tis plus T1 mucosal tumors.
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tinctiveness was assessed by calculating confidence limits of these
comparisons of P values in multivariable analysis. Homogene-
ity was assessed by analysis of residual risk,2 forcing the
current classifications and groupings into multivariable models
and identifying individual misclassifications and misgroupings.
Refining staging. Survival-tree analysis (recursive partition-
ing) analysis3 and multivariable analysis were used to determine
subclassifications of TNM that identified monotonic, distinctive,
and homogeneous survival (appendix). Subclassifications of TNM
that did not contribute to monotonic, distinctive, and homogeneous
survival were discarded.
For multivariable analysis, both Cox proportional hazard
and hazard function nonproportional methods4 were used. All
subclassifications of TNM and their interactions were exam-
ined.
Histopathologic type and grade were added to both the recur-
sive partitioning analysis and the multivariable analysis to identify
additional refinement of staging.
Stage groupings were first assigned based on AJCC guidelines
that fix stage 0 and stage IV (constrained). The unassigned ana-
tomic classifications were then assigned to stage I, II, or III based
on recursive partitioning analysis and multivariable analysis.
These groupings were verified by both methods of multivariable
analysis and by analysis of residual risk to identify and correct
residual inhomogeneity and to maximize goodness of fit (likeli-
hood).
Stage groupings were then freed from AJCC constraints (un-
constrained), and the analyses were repeated to allow TNM clas-
sifications to be freely assigned to 1 of 5 stage groupings (although
4 groupings were found to be adequate).
Results
Adequacy of Current Staging
In the absence of regional lymph node metastases (N0)
and distant metastases (M0), current T classifications
Figure 2. Survival after esophagectomy in pN1 M0 disease. A, pN1 disease (n 204, 12 traced at 5 years) contrasted
with pN0 disease (n  234, 67 traced at 5 years). B, pN1 disease stratified according to the number of regional
lymph nodes containing metastatic cancer: 1 or 2 nodes (n  83, 10 traced at 5 years) or 3 or more nodes (n  121,
2 traced at 5 years). C, pN1 disease stratified according to T. Number of patients in each subclassification and
number traced at 5 years, respectively, were as follows: T1 (11 and 1), T2 (17 and 1), T3 (169 and 9), and T4 (7 and 1).
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were monotonic and distinctive (Figure 1, A, and Table
3). Current classification of T1 tumors was inhomoge-
neous. Homogeneous classifications were obtained by
dividing T1 into T1a (intramucosal) and T1b (submuco-
sal; Figure 1, B, and Table 3). Within T1, there was a
monotonically decreasing and distinctive survival with
increasing depth of tumor invasion from the mucosa to
the submucosa.
In the absence of distant metastases (M1), the current N
classification was monotonic and distinctive (Figure 2, A,
and Table 4). However, N1 was inhomogeneous. Survival
decreased as the number of regional lymph node metastases
increased (Figure 2, B, and Table 4; P  .0001). In contrast
to N0, stratification of N1 tumors by T classification was
monotonic but not distinctive (Figure 2, C, and Table 4).
The current M classifications were monotonic and dis-
tinctive; however, within M1, survival was homogeneous
(Figure 3 and Table 4).
Current stage groupings were monotonic (Figure 4 and
Table 5). They were distinctive for stages I, IIA, and III and
possibly for 0 versus I, but not for IIB versus III versus IV
(Figure 4 and Table 5).
Refining Staging
Subclassification of TNM. Analysis of residual risk
suggested subclassifying T1 into T1a (intramucosal) and
T1b (submucosal; Figure 1, B, and Table 3) and subclassi-
fying N1 by the number of metastatic regional lymph nodes
(Figure 2, B, and Table 4). For purposes of distinct and
homogeneous subclassifications, regional lymph node me-
tastases were best classified as N1 (2 metastatic regional
lymph nodes) and N2 (3 metastatic regional lymph nodes;
Figure 2, B, and Table 4). Subclassifying M1 into M1a and
M1b did not provide distinctive prognostic information
because survival was homogeneous (Figure 3 and Table 4).
Additional factors. Histopathologic type (P  .17) and
grade (P  .3) provided little additional prognostic infor-
mation for M0 tumors by multivariable analysis. Recursive
partitioning analysis suggested that adenocarcinoma and
higher-grade cancer resulted in poorer survival and refined
classification of M1 tumors.
Redefinition of stage groupings. Current stage group-
ings were inhomogeneous. Analysis of residual risk identi-
fied patients in 4 TNM classifications whose survival was
not well represented by this grouping (P  .05, Table 6).
These were (1) submucosal cancers without regional lymph
node metastases (T1b N0 M0), which are currently grouped
with intramucosal cancers in stage I; (2) T2 N0 M0 cancers,
which are currently grouped in stage IIA; (3) T3 N0 M0
cancers, which are currently grouped in stage IIA; and (4)
tumors with 3 or more regional lymph node metastases,
which are currently grouped in both stages IIB and III.
Based on the above refinements of TNM classification
(Table 7 and Appendix Table 1), optimal stage groupings
were constructed (Figure 5 and appendix). Unconstrained
stage grouping produced 4 distinct groups with monotoni-
cally decreasing survival that were reasonably homoge-
neous within groups. Compared with current groupings, this
system improved the monotonicity, distinctiveness, and ho-
mogeneity of other classifications.
Discussion
TNM staging is a powerful tool that plays a major role in
treatment decisions, prognostication, and research. How-
ever, the process of staging cancer is dynamic. As knowl-
edge of the disease and its treatment and experience with
staging increase, there is an inherent need for revision of
Figure 3. Survival after esophagectomy stratified by M1a (n  26,
none alive at 5 years) and M1b (n  16, none alive at 5 years).
Figure 4. Survival after esophagectomy according to current AJCC
stage groupings. Number of patients in each grouping and num-
ber traced at 5 years, respectively, were as follows: 0 (44 and 21),
I (98 and 26), IIA (88 and 20), IIB (28 and 2), III (100 and 10), IVA (26
and 0), and IVB (16 and 0).
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staging. The first practical TNM staging of esophageal
cancer was introduced in 1987 and revised most recently in
2002.1,5 However, further revisions are and will be required
to improve staging of esophageal cancer.
Balch and colleagues6,7 introduced a strategy to refine
and improve staging of melanoma. We have used their
combination of algorithmic and regression analyses to as-
sess monotonicity and distinctiveness of survival. Analysis
of residual risk has been added to improve homogeneity of
classification and stage groupings. This combination analy-
sis should be considered in future refinements of cancer
staging. Further methodological refinement to minimize
misclassification in series with larger number of patients
would require the addition of multidimensional algorithmic
modeling.8
TNM Classifications
For patients without metastases to regional lymph nodes
(N0) or distant sites (M0), depth of tumor invasion (T) is
remarkably monotonic and distinctive for survival. How-
ever, within T1, survival is not homogeneous. This re-
quires reclassifying T1 tumors into T1a (intramucosal)
and T1b (submucosal) to produce distinct classes. Both
clinical staging by endoscopic ultrasonography and
pathologic staging allow differentiation of T1a from T1b
cancers. This is a practical classification that improves
staging.9 It is noteworthy that neither the AJCC nor the
International Union Against Cancer (UICC) mentions the
muscularis mucosae specifically in the definition of T1
tumors.1,5 This omission must be addressed in future
definitions of T1 classification.
For patients without distant metastases (M0), the cur-
rent N classification is monotonic and distinctive. How-
ever, for patients with regional lymph node metastases
(N1), stratification on the basis of depth of tumor inva-
sion is not distinctive. Within N1 classification, survival
is not homogeneous. Increasing lymph node burden, as
reflected by the number of regional nodes that contain
metastases, is associated with poorer survival.10,11 For
purposes of staging, distinctive survival is produced by
classifying regional lymph node metastases into N1 (2
nodes) and N2 (3 nodes). Survival differences are so
small that only one factor is necessary to account for
them. The number of regional nodal metastases is the one
factor identified by the analyses; the percentage of re-
sected lymph nodes containing metastases adds no fur-
ther information. This finding might account for apparent
discrepancies between our proposed refinement of stag-
ing and that of Korst and colleagues,12 which was based
on univariable analyses.
The current classification of distant metastatic disease
(M1) is monotonic and distinctive. Survival of patients with
M1 disease is poor and homogeneous for all T and N
classifications. Distinctive survival is not produced by the
subclassification into M1a and M1b, and thus this subclas-
sification should be abandoned.13 Although Steup and col-
leagues14 disagree with this finding, their data support the
homogeneity of survival within these subclassifications.
TABLE 4. Regional lymph node status (N), metastatic disease (M), and survival
Classification Coefficient  SE P value
Hazard
ratio 95% CL
N in pM0 disease
pN1 vs pN0 1.44 0.135 .0001 4.2 3.2-5.5
N and T* in pN1 M0
More metastatic nodes† 0.30 0.120 .01 1.35 1.07-1.71
pT1 0.88 0.57 .12 0.41 0.136-1.26
pT2 0.58 0.49 .24 0.56 0.22-1.47
pT3 0.36 0.42 .39 0.70 0.30-1.59
M
pM1 vs pM0 1.12 0.178 .0001 3.1 2.2-4.3
M in pM1 disease
pM1b vs pM1a 0.33 0.34 .9 1.39 0.7-2.7
CL, Confidence limits.
*Compared with pT4 tumors.
†Ln (number of regional lymph nodes containing metastatic cancer) natural logarithmic transformation; coefficient and hazard ratio are for a log unit increase.
TABLE 5. Current stage groupings and survival
Stage
grouping* Coefficient  SE P value
Hazard
ratio 95% CL
I 0.76 0.46 .1 2.1 0.87-5.3
IIA 1.94 0.43 .0001 7.0 3.0-16.1
IIB 2.4 0.46 .0001 10.8 4.4-27
III 2.8 0.42 .0001 16.4 7.2-37
IVA 3.1 0.46 .0001 23 9.1-56
IVB 3.5 0.49 .0001 33 12.6-86
CL, Confidence limit.
*Compared with stage 0.
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Stage Groupings
Stage groupings assemble the multiple variables of TNM
classifications into a small number of homogeneous clusters
with monotonic and distinctive survival. Current stage
groupings follow a pattern of increasing T, followed by
increasing N and then increasing M. However, esophageal
cancers do not grow and metastasize according to this
orderly pattern. Some patients have small tumors with min-
imal invasion of the esophageal wall and a single regional
nodal metastasis that decreases survival, but not to the
extent implied by current stage groupings. In contradistinc-
tion, a patient with the same superficial cancer with exten-
sive regional lymph node metastases has a prognosis similar
to that of a patient with distant metastases. This requires
regrouping not by pattern but by distinctive and homoge-
neous survival.
Assigning stage 0 to only HGD and stage IV to only
distant metastases, as in the current AJCC guidelines,1 lim-
its the definition of distinct and homogeneous groups. Pa-
tients with cancer confined to the epithelium (Tis N0 M0)
have a survival that is not distinct from those with invasion
beyond the basement membrane to involve either the lamina
propria or muscularis mucosae (T1a N0 M0). This grouping
is clinically practical because distinguishing HGD from
intramucosal cancer might be difficult even for the most
experienced pathologist.15 Patients with cancers that invade
adjacent structures and metastasize to 1 or 2 regional lymph
nodes (T4 N1 M0) and patients with multiple regional
lymph node metastases (T1-3 N2 M0) do as poorly as those
with distant metastases (M1). Freeing of the upper and lower
constraints on grouping thus permits improved staging.
The goal of stage grouping is to condense TNM classi-
fication into a small and convenient number of groups to
allow tabulation and analysis.1 The designation of stage 0
(HGD) and stage IV (M1) forces use of 5 stage groupings.
There has been a trend toward making stage groupings more
complex by introducing subgroups, such as A and B. These
designations and trends defeat the purpose of stage grouping.
Free assignment of stage groupings for esophageal cancer
requires only 4 stages to represent survival adequately.
Additional Factors
TNM descriptors are unique to each cancer and, in addition
to anatomic extent, may include such nonanatomic factors
as histopathologic type (thyroid), histopathologic grade
(sarcomas), serum biologic markers (testis), and patient
demography (thyroid and gestational trophoblastic tu-
mors).1 Addition of histopathologic type or grade did not
improve staging of esophageal cancers. Further staging
classifications of esophageal cancer await identification of
nonanatomic factors that predict survival and add additional
information not provided by TNM classifications.
Strengths and Weaknesses
Although a single-institution study might be limited in
numbers and ability to generalize inferences, its strength is
TABLE 6. Residual risk analysis of stage groupings
Stage grouping Coefficient  SE P value
Hazard
ratio 95% CL
Stage*
I† 0.45 0.50 .4 1.57 0.6-4.2
IIA‡ 2.2 0.43 .0001 8.6 3.7-20
IIB 2.1 0.47 .0001 8.6 3.4-21
III 2.5 0.43 .0001 12.4 5.3-29
IVA§ 3.2 0.46 .0001 24 9.6-59
IVB§ 3.6 0.49 .0001 35 13.4-91
Additional groups
pT1b N0 M0 or pT1a N1 M0† 0.76 0.37 .04 2.1 1.03-4.5
pT2 N0 M0‡ 0.66 0.29 .03 0.52 0.29-0.92
pT4 N1 M0 or pTany N2 M0 0.54 0.160 .0007 1.71 1.25-2.3
CL, Confidence limits.
*Compared with stage 0.
†Suggests Tis (stage 0) and pT1a N0 M0 (residual after accounting for pT1a N1 M0 and pT1b N0 M0) for a single-stage grouping.
‡Suggests these patients are at lower risk than remaining stage IIA.
§Suggests stage IVA (M1a) and stage IVB (M1b) should be coalesced into a single group.
Suggests these patients are at higher risk than remainder of stage III, and more similar to stage IV.
TABLE 7. Refined stage groupings
Stage Constrained* Unconstrained
0 Tis (HGD) —
I T1a N0 M0 Tis (HDG), T1a N0 M0
II T1b N0 M0, T1a N1 M0 T1b N0 M0, T1a N1 M0
T2 N0 M0 T2 N0 M0
III T3 N0 M0, T1b/T2 N1 M0 T3 N0 M0, T1b/T2 N1 M0
T3 N1 M0, T4 N0 M0 T3 N1 M0, T4 N0 M0
T4 N1 M0, Tany N2 M0 —
IV M1 T4 N1 M0, Tany N2 M0
M1 M1
*By AJCC definition of stage 0 and stage IV.
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uniformity of patient selection, clinical staging, treatment
decisions, surgical technique, postoperative care, and patho-
logic staging. This study has been purposely limited to
surgical therapy, avoiding influences of multimodality ther-
apy, which includes induction toxicity, biologic processes
(eg, hysteresis effect of downstaging), and disease progres-
sion during therapy.16,17 This staging system is valid and
useful for both clinical and pathologic staging. A limitation
of this strategy is that few patients with locally advanced T4
tumors are available for analysis, limiting the ability to
recognize distinctiveness and homogeneity in locally ad-
vanced disease. We have not included completeness of
resection in T classification because this is a surgical deter-
minant and not a tumor characteristic.18
Survival of patients who have undergone esophagectomy
for cancer does not reflect the natural history of untreated
disease. This is in part why staging is dynamic: it will
change as therapy evolves. Furthermore, staging might dif-
fer for patients treated nonsurgically or by combination
therapy. In all these instances, survival is influenced by
many factors, of which disease stage is but one. Patient
demographics, clinical status, clinical staging, surgical ap-
proach, and postoperative care are at play, and a combina-
tion of factors will best predict survival and direct decision
making and treatment.9,13,14,16,17
The utility of this refinement of esophageal cancer stag-
ing depends on modern clinical staging tools and complete
pathologic assessment. Currently, endoscopic esophageal
ultrasonography with fine-needle aspiration of lymph nodes
and the combination of computed tomography and fluoro-
deoxyglucose positron emission tomography provide the
most accurate clinical staging. Pathologic staging requires
resection of the primary tumor, assessment of adjacent
organs, adequate lymphadenectomy or lymph node sam-
pling, and assessment of accessible distant sites.
We thank Diane Baisden for data management and Tess Knerik
for editorial assistance.
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Appendix: Refining Staging
Subclassification of TNM
Recursive partitioning analysis for constant hazard, log rank,
Gordon-Olshen, adaptive normalization, and global normalization
methods were used for child partitioning and pruning according to
Figure 5. Survival after esophagectomy according to refined stage
groupings free of AJCC constraints (unconstrained). Number of
patients in each grouping and number traced at 5 years, respec-
tively, were as follows: I (110 and 39), II (49 and 16), III (138 and
22), and IV (167 and 2).
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monotonicity and distinctiveness of survival3 (Appendix Figure 1).
Partitions were further coalesced to provide homogeneous sur-
vival. Within each partition there could be 1 or more classifica-
tions.
Redefinition of Stage Groupings
We initially allowed subgroupings (A, B, C) of groups 0 to IV that
represented major lack of homogeneity within stage groupings.
Within each stage grouping of constrained and unconstrained
systems, inhomogeneity within groups was addressed by assign-
ment to substages.
Constrained grouping produced lack of distinctiveness at the
extremes of stage groupings (stages 0 and IV). Criteria set forth by
the AJCC were best met by a redefined unconstrained staging
system (Appendix Table 1 and Appendix Figure 2, A and B).
Seven stage groupings were identified by the unconstrained anal-
yses (Appendix Table 1). However, it was clear that the analysis
had produced 3 pairs of stages and substages for stages II, III, and
IV (Appendix Figure 2, A). Therefore, these pairs were coalesced
to yield a total of 4 major stage groupings (Figure 5).
Discussion
Dr Carolyn E. Reed (Charleston, SC). This article confirms
what most surgeons who deal with esophageal cancer know: the
present staging system is inadequate. Dr Rice and his colleagues
have used sophisticated and powerful statistical modeling to refine
the esophageal staging system.
The reclassification of T1 into T1a and T1b makes sense from
an anatomic-biologic standpoint and from the ease of identifying
these subsets by means of endoscopic ultrasonography. The addi-
tion of the number of metastatic regional lymph nodes to improve
survival stratification has been shown by others, although one
could argue about the number used as a cutoff between N1 and N2.
Appendix Figure 1. Recursive partitioning analysis of TNM clas-
sification using log-rank method. Within partitions are (1) number
of patients and (2) median survival (years).
Appendix Figure 2. Survival after esophagectomy according to
refined stage groupings. A, Groupings constrained by AJCC def-
initions of stages 0 and IV. Number of patients in each grouping
and number traced at 5 years, respectively, were as follows: 0 (44
and 21), I (66 and 18), IIA (34 and 8), IIB (31 and 8), IIIA (72 and 14),
IIIB (66 and 8), IIIC (125 and 2), and IV (42 and 0). B, Groupings free
of AJCC constraints. Number of patients in each grouping and
number traced at 5 years, respectively, were as follows: I (110
and 39), IIA (34 and 8), IIB (31 and 8), IIIA (72 and 14), IIIB (66 and
8), IVA (125 and 2), and IVB (42 and 0).
APPENDIX TABLE 1. Refined stage groupings
Stage
grouping Constrained* Unconstrained
0 Tis (HGD) —
I T1a N0 M0 Tis (HDG), T1a N0 M0
IIA T1b N0 M0, T1a N1 M0 T1b N0 M0, T1a N1 M0
IIB T2 N0 M0 T2 N0 M0
IIIA T3 N0 M0, T1b/T2 N1 M0 T3 N0 M0, T1b/T2 N1 M0
IIIB T3 N1 M0, T4 N0 M0 T3 N1 M0, T4 N0 M0
IIIC T4 N1 M0, Tany N2 M0 —
IVA M1 T4 N1 M0, Tany N2 M0
IVB M1 M1
*By AJCC definition of stage 0 and stage IV.
Rice et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 5 1111
G
TS
I accept that patients with T4 any N and T1 through T3 N2 disease
will do poorly with surgical intervention alone, mirroring patients
with metastatic disease. However, keeping some subclassification
of your unrestrained stage IV group might be useful for future
studies involving induction therapy.
I have a couple of questions for you. You had only 26 patients
with M1a disease. Because most of us are seeing large numbers of
adenocarcinomas of the gastroesophageal junction, M1a becomes
a significant subset. Does your institution offer these patients with
stage IV disease induction therapy? Should we consider a single
positive celiac lymph node either N1 and maybe stage III or
equivalent to N2? I ask this because looking at N1 versus N2 might
be important when we study the results of induction strategies.
I assume you would not offer surgical intervention alone to any
of your new patients with stage IV disease. Would you use
endoscopic ultrasonography and fine-needle aspiration results after
induction therapy to continue to deny patients surgical intervention
(ie, continued evidence of lymph nodal disease)?
I believe the time has come to redefine the staging system for
esophageal cancer. Finally, I would make a plea that staging must
incorporate endoscopic ultrasonography if it is to be considered
adequate.
Dr Rice. I would like to thank Dr Reed for her kind comments.
She is one of the pioneers in staging and has demonstrated its
importance in the treatment of esophageal cancer.
Your questions are really about the M1a group. This analysis
considers patients who undergo surgical intervention alone. There-
fore only 26 patients with M1a disease were available for analysis.
It is our practice that if we identify people with lower thoracic
esophageal cancers or cancers of the esophagogastric junction with
positive celiac nodes, we offer them induction chemoradiation
therapy. I think that if you have endoscopic ultrasonographic and
fine-needle aspiration confirmation of persistent disease after such
therapy, patients should not proceed to surgical intervention.
Dr Alan G. Casson (Halifax, Nova Scotia, Canada). I did not
see this in your abstract, and I hope I did not miss it in your talk,
but could you tell us how many of these were squamous tumors
and how many were adenocarcinomas?
Dr Rice. The majority were adenocarcinomas, approximately
80% were adenocarcinomas, and 20% were squamous cell carci-
nomas. Although I could not cover it in the presentation, we
included histologic type and grade of tumors, and by means of
recursive partitioning analysis, those factors became important
only in grouping for advanced-stage cancers, with adenocarcino-
mas doing a little bit worse than squamous cell carcinomas for the
stage IV cancers, and poorly differentiated cancers doing worse
than more differentiated cancers.
Dr Casson. Thanks for clarifying that because I think there is
increasing biologic information that these are very different dis-
eases, and I think to lump them together just because they happen
to share the same organ might not necessarily be the correct thing
to do in the future.
Dr Bryan Meyers (St Louis, Mo). Many of us have had the
experience after a transhiatal esophagectomy in which the pa-
thologist reports the T stage and then reports that there are no
lymph nodes in the resected specimen. If you call them back
and say, “You need to keep looking,” they will call back and
say, “Perhaps there were 9 or 12 lymph nodes.” I certainly
know that if you have zero lymph nodes in the specimen that N0
status means nothing. Has that ever occurred in your experi-
ence, and do you think those events occur frequently enough to
be influential in your staging algorithm? By the same token, is
there a certain number of lymph nodes that a specimen should
have to allow the results of your strategy to be generalizable to
that particular individual?
Dr Rice. The AJCC staging manual states that if there are
fewer than 6 nodes in a specimen, that is an inadequate resection.
That is the bare minimum. I think at transhiatal esophagectomy
you have to be a lymph node sampler, and the reason to add a
thoracotomy is to add lymphadenectomy for prognostication. Oth-
ers believe this should be added for therapy, but we do it at least
for prognostication. If you do not sample a lymph node, everybody
has N0 disease or NX disease, and 5-year survival is going to be
approximately 20% for all comers. Therefore I think lymph node
sampling and lymphadenectomy whenever possible are crucial to
have this staging system work.
Dr Scott J. Swanson (New York, NY). I have 2 brief questions.
One, as we do more induction therapy for these patients, does that
affect how you ultimately fit them into this new staging system?
Dr Rice. This staging system is for surgical intervention only.
What you will find with induction therapy is that it just produces
2 groups, responders and nonresponders. I plan to write about that
next. But basically there is stage I and stage II disease. Either you
respond and have an intermediate survival, or you do not respond,
have persistent disease, have nodal disease, and your survival is as
bad or worse than if we had left you alone.
Dr Swanson. I have one other related question. Given what
you see for 5-year survival, even in your stage II group, what
would you say is the best therapy for that group going forward?
Dr Rice. Well, that is always a question: when do you add
induction chemoradiation therapy? We have tended to use the
cutoff point of 50% 5-year survival, and you usually get that with
tumors confined to the esophageal wall without regional lymph
node metastases. Therefore we have made a dividing line. If you
have T2 N0 cancer or less, we will operate. If you have T3 N0 or
any N1 cancer, you will be offered induction chemoradiation
therapy because your survival with T3 N0 is around 20% to 25%
at 5 years in our experience, and with N1 cancer it is about 7%.
Dr Robert J. Ginsberg (Toronto, Ontario, Canada). I think it
was a beautiful article and a nice analysis of surgically resected
esophageal cancer, but we have to remember what the TNM
staging system is. Number one, it has to be relevant to doctors
practicing in the middle of Africa, in the middle of China, in the
middle of Indochina, as well as in the United States, where they
have endoscopic ultrasonographic and fine-needle aspiration abil-
ity. Number 2, for treatment decision making, you must perform
clinical staging. The staging system has to be relevant not only to
pathologic staging but also to clinical staging. I think you would do
us a great service if you went back and looked at the clinical stage
of those patients and once again analyzed the data and ensured that
this same distribution of survival, albeit probably lower for each
group other than stage Ia (and even that might be lower), is
relevant for clinical staging as well. There are 3 types of staging:
clinical staging; postinduction staging, which is y staging; and then
p staging, which includes all relevant information. And for every-
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body’s information, NX implies that no nodes were examined at p
staging only. At clinical staging, you have to bite the bullet and
estimate, in this case, the number of nodes. In other words, how are
you going to clinically stage the number of involved nodes in
which NX is not an option?
Dr Rice. Thank you very much for your comments.
There is no doubt that when we compare survival on the basis
of pathologic stage with that of clinical stage, it is always less. This
is particularly true with N0 cancer, but we have not examined it for
patients with N1 disease. I agree with you that it has to work for
clinical, y, and p staging. There is also r staging (retreatment) and
a (autopsy) staging. But your comments are appreciated.
Rice et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 5 1113
G
TS
